Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 11, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details a change in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan").
- Date of Movement: October 7, 2005
- Previous Holding: 18,302,665 ADRs
- New Holding: 18,341,532 ADRs
- Average Price: $51.40
This change resulted from a movement in the fund. The Plan is a discretionary fund for current and former employees. Two directors, Dr. J P Garnier and Dr. T Yamada, are noted as potentially interested in the shares held in the fund in the same capacity as other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly addresses the notification of the transaction under Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Verify the total number of ADRs held by the US Retirement Savings Plan increased by 38,867 shares.
- Confirm the average transaction price of $51.40 per ADR.
- Note that Directors Dr. J P Garnier and Dr. T Yamada have a potential interest in these shares via the employee fund, not through direct personal trading.
- Understand that this filing contains no financial performance data for the period.